Bayer Invests In Animal Medicine Lab In New Zealand



Published:

Bayer’s newly finished New Zealand laboratory has more space and equipment than the lab it supplanted.

Bayer HealthCare bolstered its Animal Health Division by spending $800,000 to upgrade a laboratory dedicated to the development of livestock and companion animal medicines.

The research facility, on the campus of the Centre for Innovation and Development in Auckland, New Zealand, focuses on new formulations and other interests, including the treatment of mastitis in dairy cows.

"This new laboratory represents Bayer’s continued commitment to developing new veterinary solutions,” said Douglas Hutchens, DVM, Ph.D., chief veterinary officer and head of global development for the Animal Health Division.

The Germany-based company in 2011 acquired New Zealand’s largest privately owned animal health company, Bomac, which operated a laboratory that the new facility replaces.

"By expanding the work of the Centre for Innovation and Development, we are investing in developments that will benefit veterinarians and farmers globally,” Dr. Hutchens said.

The $800,000 was spent on equipment and to build out previously vacant space, keeping construction costs to a minimum.

Bayer reported this month that it expects to identify new combinations of medicines for both the regional and global markets.

"Developing a new medicine for animals currently requires an investment of around 10 years and $133 million,” said Dirk Ehle, global head of the Animal Health Division. "Given the long and costly development process, it is important to fully utilize existing medicines through new formulations and novel combinations.”

Research at the New Zealand site led to Tylofen, a mastitis treatment combined with pain relief, said Derek Bartlett, country division head for Bayer HealthCare in New Zealand.

"And in the pet care segment,” Bartlett said, "the launch of Hyper-T, a transdermal treatment for hyperthyroidism in cats, has saved both owners and cats the daily stress of tablet administration.”

The 11,500-square-foot facility is staffed by 35 people who worked in the previous lab.

<HOME>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Study May Lead to Early Diagnosis of Feline Kidney Disease

The biomarker SDMA identified the onset of kidney disease an average of 17 months earlier in cats and in one case four years earlier.

Merck Launches Overseas Veterinarian Exchange

The Nobivac Global Vet Exchange Program allows practitioners to observe how veterinary medicine is performed in other countries.

Petco Buying Drs. Foster and Smith

Co-founders Race Foster and Marty Smith will stay with Drs. Foster and Smith when Petco takes ownership and branches into drug sales in early 2015.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module